Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)

Participants needed: 164
Trial details
Phase: Phase 2Age: 40+Biological sex: AllType: InterventionalSponsor: Mediar TherapeuticsUpdated: Aug 10, 2026Locations: 71
Eligibility criteria

Participants with IPF of any gender ≥ 40 years of age at time of signing the inf... [+11]

Acute exacerbation of IPF within 6 months of Screening or during the Screening P... [+19]

Read more
Status: Recruiting

EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-474 in Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Participants needed: 85
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Mediar TherapeuticsUpdated: Aug 5, 2026Locations: 58
Eligibility criteria

Diagnosis of diffuse cutaneous systemic sclerosis, classified according to 2013... [+11]

Concomitantly have another serious medical illness, which, in the opinion of the... [+22]

Read more
Status: Recruiting

Evaluation of MTX-439 in Healthy Adults and Adults With Diabetic Kidney Disease

This is a phase 1 randomized, double-blind, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, and Pharmacokinetics (PK) of single and multiple ascending doses of MTX-439 administered in healthy adults and adults with diabetic kidney disease (DKD)

Participants needed: 88
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: Mediar TherapeuticsUpdated: Jun 29, 2026Locations: 1
Eligibility criteria

All genders, ages 18 to 65 years, inclusive. [+16]

Any active medical condition determined clinically significant by the Investigat... [+20]

Read more